Human papillomavirus vaccine, L1 type 16, 18 clinical trials

Studies by the year they started

55 studies that test it; most in 2007 (10)

Who runs them

Industry 42 · Other 13

GlaxoSmithKline (40) · National Cancer Institute (NCI) (3) · London School of Hygiene and Tropical Medicine (1) · Zhejiang Provincial Center for Disease Control and Prevention (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1) · Shanghai Zerun Biotechnology Co.,Ltd (1) · University Hospital, Ghent (1) · Sanofi Pasteur, a Sanofi Company (1)

Often tested with

Tested in the same studies.

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (5) · Human Papillomavirus Recombinant Vaccine nonavalent (4) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Engerix-B (1) · Hepatitis A Vaccines (1)

Studies

Open first, then newest update. How each study uses human papillomavirus vaccine, L1 type 16, 18 is read from its arms, and is right about nine times in ten.

Testing it · 55

• Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple WartsRecruitingPhase 2Zagazig UniversityNCT05291845Written as Bivalent HPV vaccine
• Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO TrialActive, not recruitingPhase 4National Cancer Institute (NCI)NCT05237947Written as Recombinant Human Papillomavirus Bivalent Vaccine
• A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian GirlsActive, not recruitingPhase 3London School of Hygiene and Tropical MedicineNCT02834637Written as bivalent HPV vaccine
• Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 YearsActive, not recruitingPhase 4Zhejiang Provincial Center for Disease Control and PreventionNCT07281677Written as bivalent HPV vaccine
• Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO StudyActive, not recruitingPhase 4National Cancer Institute (NCI)NCT03180034Written as Recombinant Human Papillomavirus Bivalent Vaccine
• Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and YouthCompletedPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT04301154Written as Cervarix
• Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO TrialCompletedPhase 3National Cancer Institute (NCI)NCT03728881Written as Recombinant Human Papillomavirus Bivalent Vaccine
• Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy FemalesCompletedPhase 3Shanghai Zerun Biotechnology Co.,LtdNCT04965350Written as Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
• Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)CompletedPhase 4University Hospital, GhentNCT01914367Written as cervarix
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT02979535Written as Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.CompletedPhase 3GlaxoSmithKlineNCT00481767Written as Cervarix
• Reactogenicity Study of Cervarix and Gardasil in UK Adolescent GirlsCompletedPhase 4Public Health EnglandNCT00956553Written as Cervarix
• FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening ProgramCompletedPhase 4Instituto Nacional de Salud Publica, MexicoNCT03105856Written as CERVARIX
• Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected FemalesCompletedPhase 4GlaxoSmithKlineNCT01031069Written as GSK Biologicals' HPV vaccine 580299
• Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old GirlsCompletedPhase 3GlaxoSmithKlineNCT01381575Written as GSK Biologicals' HPV vaccine 580299
• Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years OldCompletedPhase 3GlaxoSmithKlineNCT01627561Written as Cervarix
• Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected FemalesCompletedPhase 2GlaxoSmithKlineNCT00586339Written as Cervarix
• Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)CompletedPhase 3GlaxoSmithKlineNCT00637195Written as Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)
• Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.CompletedPhase 3GlaxoSmithKlineNCT00250276Written as Cervarix™
• Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeCompletedPhase 3GlaxoSmithKlineNCT00423046Written as GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)

See all 55 studies that test human papillomavirus vaccine, L1 type 16, 18 →